P/E at 34.44 vs Industry's 33.21: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflects Sector Confidence

The current P/E of 34.44 for Sun Pharmaceutical Industries Ltd sits slightly above the Pharmaceuticals & Biotechnology industry average of 33.21. This premium, though not excessive, suggests investors are willing to pay a bit more for the stock relative to its peers. The valuation premium may reflect expectations of steady earnings growth or a perception of relative stability within the sector. However, the premium is modest enough to warrant scrutiny — Sun Pharma is not trading at a stretched multiple compared to the industry, which currently includes 34 stocks with 19 reporting positive results, 9 flat, and 6 negative outcomes.

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple periods reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 6.68% gain, comfortably outperforming the Sensex’s 8.46% decline. This outperformance extends to the three-month horizon, where the stock posted a 1.55% gain versus the Sensex’s 6.28% loss. However, the short-term trend is less encouraging: the stock has declined 3.71% over the past week and 2.61% in the last month, underperforming the Sensex in both periods.

This recent weakness is underscored by a five-day consecutive fall, resulting in a cumulative loss of 3.42%. The stock’s one-day performance on 4 June 2026 was down 0.72%, slightly worse than the sector’s 0.29% underperformance. The 3.30% year-to-date gain also contrasts with the Sensex’s 13.00% decline, highlighting relative resilience despite recent volatility. Sun Pharma’s 5-year return of 163.50% far exceeds the Sensex’s 42.31%, reflecting strong long-term growth, though the 10-year return of 140.64% trails the Sensex’s 176.21% over the same period.

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is nuanced. The stock currently trades above its 50-day, 100-day, and 200-day moving averages, signalling underlying medium- to long-term strength. However, it remains below the 5-day and 20-day moving averages, indicating short-term weakness or consolidation. This configuration suggests a recent pullback within a broader uptrend, but the immediate momentum is subdued. The 5-day and 20-day averages often reflect near-term investor sentiment, and the stock’s position below these levels raises questions about whether this is a temporary pause or the start of a deeper correction — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Context: Pharmaceuticals & Biotechnology Performance

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent quarters. Of the 34 stocks that have declared results, 19 reported positive outcomes, 9 were flat, and 6 posted negative results. This distribution indicates a sector with pockets of strength but also areas of concern. Sun Pharmaceutical Industries Ltd’s relative outperformance over the past year and resilience in the three-month period suggest it is among the more stable large-cap names within this sector. However, the recent short-term underperformance aligns with some sector peers facing headwinds, possibly linked to regulatory challenges or pricing pressures.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO before its rating was updated on 1 June 2026. The current Mojo Score stands at 67.0 with a Hold grade previously assigned. This reassessment reflects the evolving valuation and performance dynamics, including the modest premium in P/E and the mixed short-term momentum. The rating update invites investors to consider the balance between the stock’s long-term strength and recent volatility — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced View from Data

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a slight valuation premium within its sector, supported by solid long-term returns and relative resilience over the past year. However, recent short-term underperformance and a mixed moving average configuration suggest caution. The stock’s position above key long-term moving averages but below short-term averages indicates a potential pause or consolidation phase rather than a clear breakout or breakdown. The sector’s mixed results further underscore the need for careful analysis.

With the rating updated from Buy to Hold, investors face a nuanced decision — what is the current rating for Sun Pharmaceutical Industries Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today